Last updated: March 13, 2026
What is the indicated drug?
NDC 60505-6157 corresponds to Glatiramer Acetate, marketed as Copaxone. Approved by the FDA for multiple sclerosis (MS), it is available in various formulations, including once-daily and weekly subcutaneous injections.
Market Overview
Therapeutic Area and Market Dynamics
Glatiramer acetate is a standard disease-modifying therapy (DMT) in relapsing-remitting multiple sclerosis (RRMS). It has held a prominent market share since FDA approval in 1996. The MS treatment market size reached approximately $22 billion globally in 2022, with the US accounting for about 50%.
Key Competitors
- Interferon beta products (e.g., Avonex, Rebif)
- Oral disease-modifying therapies (e.g., Tecfidera, Aubagio, Gilenya)
- Emerging therapies (e.g., Zeposia, Mayzent)
Market Trends
- Growing MS prevalence, particularly among young adults.
- Increasing use of oral agents, exerting downward pressure on injectable DMTs like Copaxone.
- Biosimilar and generic entrants expanding competition.
Patent and Exclusivity Status
- Original patents for Copaxone expired in 2015.
- The brand retains market presence via formulation patents and exclusivity on certain formulations.
Price Analysis
Current Pricing Structure
As of early 2023:
| Formulation |
Average Wholesale Price (AWP) per dose |
Monthly Cost (30 doses) |
Annual Cost (365 doses) |
| Copaxone 20 mg daily (brand) |
~$85 per dose |
~$2,550 |
~$31,320 |
| Copaxone 40 mg weekly (brand) |
~$340 per dose |
~$1,360 (per week) |
~$70,520 (annually) |
| Generic glatiramer acetate 20 mg |
~$25 per dose |
~$750 |
~$9,150 |
Note: These prices are estimates based on wholesale data; actual patient costs vary based on insurance and rebates.
Price Trends
- The 2015 patent expiration led to a surge in generic entries, reducing prices by approximately 75% for the 20 mg formulation.
- Biosimilar and generic competitors continue to drive prices downward, with some discounts reaching 80% below brand levels.
- The 40 mg formulation, approved in 2014, maintains higher pricing but faces pressure from generics.
Market Projections
Short-term (Next 2 Years)
- Market share stabilization: Despite competition, Copaxone retains a significant portion of the MS injectable market due to physician familiarity.
- Price stability/decline: Generic competition will keep prices stable or decreasing marginally.
- Sales impact: Estimated annual sales could decline by approximately 10-15% owing to competitor entries and payer pressure.
Medium-term (3-5 Years)
- Market contraction: Some patients switch to oral therapies; injectable DMTs could lose up to 25% of their patient base.
- Pricing pressure persists: Continued commoditization of generics may push prices down further.
- Potential for biosimilar proliferation: Biosimilars might capture additional market segments, pushing prices down by an additional 50% from current generic levels.
Long-term (5+ years)
- Market share decline: Brand-specific formulations are at risk of further erosion as generics and biosimilars dominate.
- Price floors: Expected to stabilize around $10-$15 per dose for generics.
- Innovations impact: New therapies with better efficacy or safety profiles could further diminish demand for existing formulations.
Key Variables Affecting Price and Market Dynamics
- Regulatory approvals of biosimilars and generics.
- Patent litigation outcomes and new formulation patents.
- Payer reimbursement policies.
- Adoption of oral and infusion therapies.
- Clinical guidelines shifting toward newer agents.
Strategic Insights
- For investors: Focus on generic manufacturers and biosimilar developers with established market access.
- For pharma companies: Consider diversification into oral therapies or combination treatments.
- For clinicians: Migrate patients toward therapies with better adherence profiles and comparable efficacy.
Summary Table: Price Projections (2023–2028)
| Year |
Estimated Average Dose Price |
Approximate Annual Cost |
Market Share Trends |
| 2023 |
$25-$85 |
$750-$2,550 |
Slight decline, market stabilization |
| 2024 |
$20-$80 |
$600-$2,400 |
Continued decline, increased generic penetration |
| 2025 |
$15-$70 |
$450-$2,100 |
Biosimilar competition intensifies |
| 2026–28 |
$10-$50 |
$300-$1,500 |
Generics dominate, brand declines |
Key Takeaways
- NDC 60505-6157 (glatiramer acetate) has experienced significant price reductions since patent expiry.
- Market share remains, but declining due to oral DMTs and biosimilars.
- Prices for generics are projected to stabilize around $10-$15 per dose in the medium term.
- The MS injectable market will see further consolidation and commoditization over the next five years.
- Strategic focus on biosimilar development and alternative therapies is critical for stakeholders.
FAQs
Q1: How will new biosimilars affect the market price for glatiramer acetate?
A1: Biosimilars are likely to reduce prices further, potentially by 50% compared to current generic prices, increasing competition and lowering costs.
Q2: What is the impact of oral MS therapies on injectable DMTs like Copaxone?
A2: They reduce market share for injectables, leading to sales declines and potentially influencing pricing strategies.
Q3: Are there upcoming patent expirations that could further lower prices?
A3: The original patent for Copaxone expired in 2015; ongoing formulation patents may extend exclusivity but are subject to legal challenges.
Q4: What are key strategic opportunities for generic manufacturers?
A4: Expand biosimilar portfolios, optimize supply chains, and engage with payers to improve reimbursement terms.
Q5: How could clinical guidelines impact future demand?
A5: Preference for newer, more effective therapies could diminish demand for glatiramer acetate, pressuring prices downward.
References
[1] IQVIA. (2022). Global MS Market Report.
[2] FDA. (2022). Approved Drugs for Multiple Sclerosis.
[3] MarketWatch. (2023). MS Therapeutics Market Analysis.
[4] Medtrack. (2023). Biosimilar and Generic Entry Data.
[5] Center for Devices and Radiological Health. (2022). Patent and Exclusivity Data for MS Drugs.
